Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
Background: Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-caten...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/3/827 |
| _version_ | 1797488684750077952 |
|---|---|
| author | Ryu Sasaki Kazuyoshi Nagata Masanori Fukushima Masafumi Haraguchi Satoshi Miuma Hisamitsu Miyaaki Akihiko Soyama Masaaki Hidaka Susumu Eguchi Masaya Shigeno Mio Yamashima Shinobu Yamamichi Tatsuki Ichikawa Yuki Kugiyama Hiroshi Yatsuhashi Kazuhiko Nakao |
| author_facet | Ryu Sasaki Kazuyoshi Nagata Masanori Fukushima Masafumi Haraguchi Satoshi Miuma Hisamitsu Miyaaki Akihiko Soyama Masaaki Hidaka Susumu Eguchi Masaya Shigeno Mio Yamashima Shinobu Yamamichi Tatsuki Ichikawa Yuki Kugiyama Hiroshi Yatsuhashi Kazuhiko Nakao |
| author_sort | Ryu Sasaki |
| collection | DOAJ |
| description | Background: Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-catenin mutations. We evaluated whether the pretreatment of the hepatobiliary phase of EOB-MRI could predict the therapeutic effect of lenvatinib and atezolizumab plus bevacizumab. Methods: This study included 68 patients (lenvatinib group (<i>n</i> = 33) and atezolizumab plus bevacizumab group (<i>n</i> = 35)). The visual assessment and relative enhancement ratio (RER) of the largest HCC lesions were evaluated using the hepatobiliary phase of EOB-MRI. Results: The hyperintensity type (RER ≥ 0.9) was 18.2% in the lenvatinib group and 20.0% in the atezolizumab plus bevacizumab group. In the lenvatinib group, progression-free survival (PFS) was not different between the heterogeneous and homogenous types (<i>p</i> = 0.688) or between the hyperintensity and hypointensity types (<i>p</i> = 0.757). In the atezolizumab plus bevacizumab group, the heterogeneous type had significantly shorter PFS than the homogenous type (<i>p</i> = 0.007), and the hyperintensity type had significantly shorter PFS than the hypointensity type (<i>p</i> = 0.012). Conclusions: The hepatobiliary phase of EOB-MRI was useful for predicting the therapeutic effect of atezolizumab plus bevacizumab therapy on unresectable HCC. |
| first_indexed | 2024-03-10T00:05:49Z |
| format | Article |
| id | doaj.art-fb539a6fd3af42a7819f320b6d1b8810 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:05:49Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fb539a6fd3af42a7819f320b6d1b88102023-11-23T16:09:20ZengMDPI AGCancers2072-66942022-02-0114382710.3390/cancers14030827Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular CarcinomaRyu Sasaki0Kazuyoshi Nagata1Masanori Fukushima2Masafumi Haraguchi3Satoshi Miuma4Hisamitsu Miyaaki5Akihiko Soyama6Masaaki Hidaka7Susumu Eguchi8Masaya Shigeno9Mio Yamashima10Shinobu Yamamichi11Tatsuki Ichikawa12Yuki Kugiyama13Hiroshi Yatsuhashi14Kazuhiko Nakao15Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanDepartment Gastroenterology and Hepatology, Japanese Red Cross, Nagasaki Genbaku Hospital, 3-15 Mori-machi, Nagasaki City 852-8511, Nagasaki, JapanDepartment Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, 6-39 Shinchi-machi, Nagasaki City 850-8798, Nagasaki, JapanDepartment Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, 6-39 Shinchi-machi, Nagasaki City 850-8798, Nagasaki, JapanDepartment Gastroenterology and Hepatology, Nagasaki Harbor Medical Center, 6-39 Shinchi-machi, Nagasaki City 850-8798, Nagasaki, JapanClinical Research Center, National Hospital Organization Nagasaki Medical Center, Department of Hepatology, 2-1001-1 Kubara, Omura City 856-8562, Nagasaki, JapanClinical Research Center, National Hospital Organization Nagasaki Medical Center, Department of Hepatology, 2-1001-1 Kubara, Omura City 856-8562, Nagasaki, JapanDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, JapanBackground: Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-catenin mutations. We evaluated whether the pretreatment of the hepatobiliary phase of EOB-MRI could predict the therapeutic effect of lenvatinib and atezolizumab plus bevacizumab. Methods: This study included 68 patients (lenvatinib group (<i>n</i> = 33) and atezolizumab plus bevacizumab group (<i>n</i> = 35)). The visual assessment and relative enhancement ratio (RER) of the largest HCC lesions were evaluated using the hepatobiliary phase of EOB-MRI. Results: The hyperintensity type (RER ≥ 0.9) was 18.2% in the lenvatinib group and 20.0% in the atezolizumab plus bevacizumab group. In the lenvatinib group, progression-free survival (PFS) was not different between the heterogeneous and homogenous types (<i>p</i> = 0.688) or between the hyperintensity and hypointensity types (<i>p</i> = 0.757). In the atezolizumab plus bevacizumab group, the heterogeneous type had significantly shorter PFS than the homogenous type (<i>p</i> = 0.007), and the hyperintensity type had significantly shorter PFS than the hypointensity type (<i>p</i> = 0.012). Conclusions: The hepatobiliary phase of EOB-MRI was useful for predicting the therapeutic effect of atezolizumab plus bevacizumab therapy on unresectable HCC.https://www.mdpi.com/2072-6694/14/3/827atezolizumabbevacizumabbiomarkershepatocellular carcinomacateninslenvatinib |
| spellingShingle | Ryu Sasaki Kazuyoshi Nagata Masanori Fukushima Masafumi Haraguchi Satoshi Miuma Hisamitsu Miyaaki Akihiko Soyama Masaaki Hidaka Susumu Eguchi Masaya Shigeno Mio Yamashima Shinobu Yamamichi Tatsuki Ichikawa Yuki Kugiyama Hiroshi Yatsuhashi Kazuhiko Nakao Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma Cancers atezolizumab bevacizumab biomarkers hepatocellular carcinoma catenins lenvatinib |
| title | Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma |
| title_full | Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma |
| title_fullStr | Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma |
| title_short | Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma |
| title_sort | evaluating the role of hepatobiliary phase of gadoxetic acid enhanced magnetic resonance imaging in predicting treatment impact of lenvatinib and atezolizumab plus bevacizumab on unresectable hepatocellular carcinoma |
| topic | atezolizumab bevacizumab biomarkers hepatocellular carcinoma catenins lenvatinib |
| url | https://www.mdpi.com/2072-6694/14/3/827 |
| work_keys_str_mv | AT ryusasaki evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT kazuyoshinagata evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT masanorifukushima evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT masafumiharaguchi evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT satoshimiuma evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT hisamitsumiyaaki evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT akihikosoyama evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT masaakihidaka evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT susumueguchi evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT masayashigeno evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT mioyamashima evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT shinobuyamamichi evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT tatsukiichikawa evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT yukikugiyama evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT hiroshiyatsuhashi evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma AT kazuhikonakao evaluatingtheroleofhepatobiliaryphaseofgadoxeticacidenhancedmagneticresonanceimaginginpredictingtreatmentimpactoflenvatinibandatezolizumabplusbevacizumabonunresectablehepatocellularcarcinoma |